Steven R. Levine MD, FAHA, FAAN, FANAProfessor of Neurology & Emergency Medicine; Vice Chair, Neurology; Chief of Neurology, University Hospital of Brooklyn; The State University of New York (SUNY) Health Science Center, Brooklyn, New York
Dr. Levine is a Professor of Neurology & Emergency Medicine and Vice Chairman of Neurology. Dr. Levine’s Clinical Research interests are in cerebrovascular disease and stroke. He was the Detroit area PI for the NIH-funded NINDS rt-PA Stroke Trial that led to FDA approval of the first treatment for acute ischemic stroke – tissue plasminogen activator (tPA). He has served as the Editor-in-Chief of the National Stroke Association’s Stroke-Clinical Updates and serves/served on the Editorial Boards of several peer-reviewed journals, including Neurology, Stroke, Future Neurology, Medicine, and Clinical Neuropharmacology. He serves as a consultant for NIH, AHA/ASA, NSA, and the pharmaceutical industry. Dr. Levine is local PI for 2 NINDS clinical trial networks (NETT, NeuroNEXT).
Disclosures: Steering Committee, PRISMS, a Genentech-funded randomized clinical trial of intravenous t-PA for minor stroke: modest honorarium and travel expenses